Our Facility Capacity
Equipped with advanced equipment, AskGene Pharma, Inc. is capable of performing molecule screenings, cell line development, small scale upstream/downstream process development, and bioanalysis. Our business strategy, as of now, is to do the early stage molecule discovery/evaluation and small scale process development in house while also collaborating with CMOs/CROs during the IND enabling stage. By working closely with CMOs, like Wuxi Biologics and Tmab, our team has successfully filed three biological INDs to China’s FDA and one to EMA. We are currently undergoing construction of our pilot plant in Nanjing, China, and expect it be completed in 2019.